Coagulation Factor Xa Stimulates Interleukin-8 Release in Endothelial Cells and Mononuclear Leukocytes: Implications in Acute Myocardial Infarction

Objective— In acute myocardial infarction (AMI), proinflammatory plasma C-reactive protein values are strongly associated with postinfarction morbidity and mortality. So far, the cause of these inflammatory changes is not well understood. Therefore, we sought to investigate the relationship between the activation of coagulation and subsequent systemic inflammatory changes in AMI. Methods and Results— Factor Xa (FXa) bound to tissue factor pathway inhibitor and prothrombin fragments F1+2 (F1+2) were used as a measure for activated coagulation. To assess systemic inflammatory changes, plasma interleukin (IL)-6 and IL-8 concentrations were analyzed by immunoassay. Blood samples were taken from 21 patients with AMI and 20 patients with stable angina pectoris. In AMI, tissue factor pathway inhibitor FXa but not F1+2 plasma levels were associated with circulating IL-8 (P=0.01). In vitro experiments revealed that FXa stimulated IL-8 and monocyte chemoattractant protein-1 release and RNA expression in endothelial cells and mononuclear leukocytes by activation of protease-activated receptor-1. Conclusion— Our data suggest that coagulation FXa may contribute to proinflammatory changes in AMI by stimulation of IL-8 release. Therapeutic inhibition of the proinflammatory effects of FXa may improve the clinical course in AMI.

[1]  F. Neumann,et al.  Effect of human recombinant interleukin-6 and interleukin-8 on monocyte procoagulant activity. , 1997, Arteriosclerosis, thrombosis, and vascular biology.

[2]  F. Neumann,et al.  Procoagulant inflammatory responses of monocytes after direct balloon angioplasty in acute myocardial infarction. , 1998, The American journal of cardiology.

[3]  A. Rebuzzi,et al.  The prognostic value of C-reactive protein and serum amyloid a protein in severe unstable angina. , 1994, The New England journal of medicine.

[4]  N. Mackman.  Regulation of the tissue factor gene , 1995, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[5]  F. Ofosu,et al.  Probable regulation of factor VIIa–tissue factor and prothrombinase by factor Xa–TFPI and TFPI in vivo , 1996, British journal of haematology.

[6]  M. Andrassy,et al.  Regulation of monocyte procoagulant activity in acute myocardial infarction: role of tissue factor and tissue factor pathway inhibitor-1. , 2001, Blood.

[7]  T. Cocks,et al.  Increased Expression of Protease-Activated Receptor-2 (PAR2) and PAR4 in Human Coronary Artery by Inflammatory Stimuli Unveils Endothelium-Dependent Relaxations to PAR2 and PAR4 Agonists , 2001, Circulation research.

[8]  Y. Itoyama,et al.  Transient increase of cytokine-induced neutrophil chemoattractant, a member of the interleukin-8 family, in ischemic brain areas after focal ischemia in rats. , 1995, Stroke.

[9]  C. Morys-Wortmann,et al.  Endothelial protease‐activated receptor‐2 induces tissue factor expression and von Willebrand factor release , 1999, British journal of haematology.

[10]  A. Siegbahn,et al.  Low-molecular Weight Heparin Reduces the Generation and Activity of Thrombin in Unstable Coronary Artery Disease , 1998, Thrombosis and Haemostasis.

[11]  S. Coughlin,et al.  Genetic Evidence That Protease-activated Receptors Mediate Factor Xa Signaling in Endothelial Cells* , 2002, The Journal of Biological Chemistry.

[12]  R. Giugliano,et al.  Meta-analysis of corticosteroid treatment in acute myocardial infarction. , 2003, The American journal of cardiology.

[13]  R. Berge,et al.  Interaction between chemokines and oxidative stress: possible pathogenic role in acute coronary syndromes. , 2001, Journal of the American College of Cardiology.

[14]  F. Neumann,et al.  Cardiac release of chemoattractants after ischaemia induced by coronary balloon angioplasty. , 1993, British heart journal.

[15]  D. Ardissino,et al.  Thrombin activity and early outcome in unstable angina pectoris. , 1996, Circulation.

[16]  H. Hemker,et al.  Factor Xa induces cytokine production and expression of adhesion molecules by human umbilical vein endothelial cells. , 1998, Journal of immunology.

[17]  E. Antman,et al.  Enoxaparin prevents death and cardiac ischemic events in unstable angina/non-Q-wave myocardial infarction. Results of the thrombolysis in myocardial infarction (TIMI) 11B trial. , 1999, Circulation.

[18]  M. Simionescu,et al.  A Novel Attribute of Enoxaparin: Inhibition of Monocyte Adhesion to Endothelial Cells by a Mechanism Involving Cell Adhesion Molecules , 2002, Pharmacology.

[19]  G. D. Hunter,et al.  Proteinase-activated receptors. , 2001, Pharmacological reviews.

[20]  A. Siegbahn,et al.  Relationship between interleukin 6 and mortality in patients with unstable coronary artery disease: effects of an early invasive or noninvasive strategy. , 2001, JAMA.

[21]  B. Lucchesi,et al.  C-Reactive-Protein-Associated Increase in Myocardial Infarct Size After Ischemia/Reperfusion , 2002, Journal of Pharmacology and Experimental Therapeutics.

[22]  V. Ramakrishnan,et al.  The Proteinase-activated Receptor 2 Is Induced by Inflammatory Mediators in Human Endothelial Cells , 1996, The Journal of Biological Chemistry.

[23]  M. Dalby,et al.  Comparison of effects on markers of blood cell activation of enoxaparin, dalteparin, and unfractionated heparin in patients with unstable angina pectoris or non-ST-segment elevation acute myocardial infarction (the ARMADA study). , 2003, The American journal of cardiology.

[24]  W Ruf,et al.  Gene induction by coagulation factor Xa is mediated by activation of protease-activated receptor 1. , 2001, Blood.

[25]  M. Schwaiger,et al.  Predictive value of basal C-reactive protein levels for myocardial salvage in patients with acute myocardial infarction is dependent on the type of reperfusion treatment. , 2003, European heart journal.

[26]  P. Thompson,et al.  Activation of Protease-Activated Receptor (PAR)-1, PAR-2, and PAR-4 Stimulates IL-6, IL-8, and Prostaglandin E2 Release from Human Respiratory Epithelial Cells1 , 2002, The Journal of Immunology.

[27]  J. Freyssinet,et al.  Elevated levels of shed membrane microparticles with procoagulant potential in the peripheral circulating blood of patients with acute coronary syndromes. , 2000, Circulation.

[28]  C. Dinarello,et al.  Anticytokine strategies in the treatment of the systemic inflammatory response syndrome. , 1993, JAMA.

[29]  Kathleen M. Smith,et al.  Localization of tissue factor in the normal vessel wall and in the atherosclerotic plaque. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[30]  Y. Nemerson,et al.  Alternatively spliced human tissue factor: a circulating, soluble, thrombogenic protein , 2003, Nature Medicine.

[31]  R. Santucci,et al.  Inhibition of the tissue factor-thrombin pathway limits infarct size after myocardial ischemia-reperfusion injury by reducing inflammation. , 2000, The American journal of pathology.

[32]  Y. Yamaguchi,et al.  Anticoagulant pretreatment attenuates production of cytokine-induced neutrophil chemoattractant following ischemia-reperfusion of rat liver , 1996, Digestive Diseases and Sciences.

[33]  R. Frazier,et al.  Recombinant E. coli-derived tissue factor pathway inhibitor reduces coagulopathic and lethal effects in the baboon gram-negative model of septic shock. , 1994, Circulatory shock.

[34]  A. Moss,et al.  Thrombogenic factors and recurrent coronary events. , 1999, Circulation.

[35]  A. Lindahl,et al.  Elevated plasma levels of the factor Xa-TFPI complex in cancer patients. , 2002, Thrombosis research.